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Abstract: 18 
Flavonoids, a group of secondary metabolites widely distributed in the plant kingdom, have been 19 
acknowledged for their interesting medicinal properties. Among them, natural flavones, as well as some 20 
of their synthetic derivatives, have been shown to exhibit several biological activities, including 21 
antioxidant, anti-inflammatory, antitumor, anti-allergic, neuroprotective, cardioprotective and 22 
antimicrobial.  The antioxidant properties of flavones allow them to demonstrate potential application as 23 
preventive and attenuating agents in oxidative stress, i.e., a biological condition that is closely associated 24 
to aging process and to several diseases. Some flavones interfere in distinct oxidative-stress related events 25 
by directly reducing the levels of intracellular free radicals (hydroxyl, superoxide and nitric oxide) and/or 26 
of reactive species (e.g. hydrogen peroxide, peroxynitrite and hypochlorous acid) thus preventing their 27 
amplification and the consequent damage of other biomolecules such as lipids, proteins and DNA. 28 
Flavones can also hinder the activity of central free radical-producing enzymes, such as xanthine oxidase 29 
and nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase) or inducible nitric oxide 30 
synthase (iNOS) and can even modulate the intracellular levels of pro-oxidant and/or antioxidant 31 
enzymes. The evaluation of flavones antioxidant ability has been extensively determined in chemical or 32 
biological in vitro models, but in vivo therapy with individual flavones or with flavones-enriched extracts 33 
has also been reported. The present manuscript revises relevant studies focusing the preventive effects of 34 
flavones on stress-related diseases, namely the neurological and cardiovascular diseases, and diabetes and 35 
its associated complications. 36 
 37 
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1. INTRODUCTION 46 
1.1. General Structure and Function 47 
Flavones are one of the main classes of flavonoids i.e., a group compounds characterized by a 48 
C15 basic skeleton composed of a benzene ring (A-ring) fused to a heterocyclic pyran ring (C-ring), 49 
having a phenyl substitution most often at the 2-position (B-ring). In particular, flavones are characterized 50 
by the presence of a double bond between the 2- and 3- positions in the heterocyclic C-ring and the 51 
lacking of oxygenation at the 3-position of the same ring (Fig. 1). 52 
Typical variations in the basic structure of the flavones include OH- and OMe-substitution, 53 
mainly in the A- and B-rings. Other groups such as C-methyl, methylenedioxy, C- and O-prenyl, pyran, 54 
furan and aromatic have also been described [1]. Moreover, natural flavones occur as aglycone or 55 
alternatively, as hexosides or acylated glucosides [2].  56 
 57 
 58 
 59 
Fig. (1). General structure of flavones. 60 
 61 
 The natural flavones are secondary metabolites from vascular plants and, likewise other 62 
flavonoids, they are key players in plant development and growth. Some flavones are also involved in 63 
plant survival due their ability to act as ultraviolet filters, as well as to protect the plants from microbial, 64 
insect and even from mammalian herbivor attack [2-3]. Althoug flavones are classified as colourless 65 
compounds, they can act as co-pigments of anthocyanins, providing attractive colours to plant pollinators 66 
[2-3]. 67 
 Main natural flavones comprise chrysin, balcalein, scutellarein, nobiletin, luteolin, apigenin, 68 
tangeritin and 6-hydroxyflavone. From those, luteolin and apigenin are widespread in grains, leafy 69 
vegetables, and herbs and are considered to be the most representative ones in food sources [1, 4]. High 70 
concentrations of luteolin are particularly found in celery seeds (aproximatly 800 mg/100 g) while 71 
moderate amounts are found in thyme, sage, oregano, olives, peppermint, green peppers, chilli pepper 72 
green, parsley, lemon, red lettuce and sweet pepper red. Apigenin is mainly found in parsley and celery 73 
seeds [1, 5].  74 
 The daily intake of flavones is widely variable amongst populations, depending on their specific 75 
dietary food habits. It has been estimated that the mean intake of apigenin and luteolin by Chinese 76 
population is aproximatly 1.1 and 3.8 mg/day [6], respectively, while the total intake of these two 77 
flavones by Australian and Spanish populations accounts up to 0.05 and 3.6 mg/day [7], [8]. Correlations 78 
between the intake of flavones and their in vivo effects are still under debate, as their bioavailability is not 79 
completely elucidated. Indeed, although it is presently accepted that ingested flavones (likewise other 80 
simple phenolics) can be partially absorbed in the small intestine and suffer metabolization in the liver as 81 
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signalization for excretion from the body, further studies need to be carried out in order to fully 82 
understand the effective concentrations of flavones in the target organs (e.g elucidation of absorbable 83 
low-molecular-weight phenolic metabolites which are produced by gut microbial flora and possible 84 
accumulation in body tissues) [5, 9]. 85 
 86 
 87 
1.2. Oxidative Processes 88 
 Mitochondria is the primary site of generation of reactive oxygen species (ROS) in aerobic cells, 89 
since the univalente reduction of triplet-state molecular oxygen results in the production of superoxide 90 
anion (O2
•¯
) [10]. This species can also be produced by other celular enzymes such as xanthine oxidase 91 
and NADPH-oxidases (Fig. 2). Despite the relatively low reactivity of O2
•¯
, this species can be converted, 92 
through enzymatic or nonenzymatic reactions, to highly reactive ROS (e.g. hydroxyl radical (OH
•
)) or 93 
reactive nitrogen species (RNS), namely peroxynitrite (ONOO
¯
) [11]. The former results from its 94 
conversion of O2
•¯
 to hydrogen peroxide (H2O2) and it’s subsequent reduction, which occurs either in the 95 
absence or in the presence of reduced transition metals. In turn, ONOO
¯
 results from the reaction of O2
•¯
 96 
with nitric oxide (NO
•
), a reactive species that is produced by nitric oxide synthases (NOS) when 97 
converting arginine into citruline. Elevated amounts of NO
•
 are particularly produced by inducible nitric 98 
oxide synthase (iNOS), a pro-oxidant enzyme which is highly expressed in inflammatory cells upon 99 
stimulation by exogenous or endogenous stimuli [12-15].   100 
 101 
 102 
 103 
Fig. (2). Schematic representation of formation and enzymatic neutralization processes of the superoxide radicals and 104 
its derivatives. Superoxide anion (O2•¯) is converted into the ONOO¯ (a highly reactive species), in the presence of 105 
nitric oxide (NO•), thus causing serious cellular damages that might end in necrosis and/or apoptosis. In turn, 106 
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superoxide dismutase (SOD) is an antioxidant enzyme capable of converting O2•¯ into hydrogen peroxide (H2O2). 107 
The latter might follow two paths: 1- In presence of Fe2+, the Fenton reaction occurs, converting H2O2
 into hydroxyl 108 
radicals (OH•) which, similarly to ONOO¯, is highly reactive and will cause cellular damage/death; 2- Converted into 109 
water (H2O) and oxygen (O2) by the antioxidant enzymes catalase (CAT) or glutathione peroxidase (GSH-px). This 110 
latter enzyme uses the reduced form of glutathione (GSH) as an electron donor to convert the H2O2, producing 111 
gluthatione disulfide (GSSG), which in turn can be converted back again into GSH by glutathione reductase (GSSG-112 
red) using NADPH as an electron donor. 113 
 114 
 Notably, cells have several mechanisms to maintain the redox homeostasis, i.e., the balance 115 
between ROS and RNS generation and their elimination [16]. The consumption or deactivation of said 116 
compounds occurs via the action of both enzymatic and non-enzymatic/simple antioxidants [11, 17]. For 117 
instance, superoxide radical is converted to oxygen and hydrogen peroxide by the enzyme superoxide 118 
dismutase (SOD) where the latter is transformed to water and oxygen by the enzyme catalase (CAT), 119 
while glutathione peroxidase (GSH-px) reduces lipid hydroperoxides to their corresponding alcohols and 120 
reduces free hydrogen peroxide to water (see Fig. 2) [18]. The latter enzyme makes use of glutathione 121 
(GSH) as an electron donor, converting it into glutathione disulfide (GSSG), which in turn is regenerated 122 
by glutathione reductase (GSSG-red) into GSH again. Therefore, GSH is a pivotal endogenous molecule 123 
on cellular antioxidant defenses. It is also important to refer to the central role of the nuclear factor 124 
(erythroid-derived 2)-like 2 (Nrf2), which is known as the “master regulator” of the antioxidant response, 125 
since it is responsible for the modulation of the expression of hundreds of genes, including those that 126 
encode the antioxidant enzymes mentioned before. The activity of this transcription factor is triggered on 127 
oxidative stress conditions, causing its translocation to the nucleus where it will upregulate the expression 128 
of several genes of antioxidant and cytoprotective enzymes in order to restore the balance. In turn, 129 
vitamin A, C and E, as well as caffeine are examples of non-enzymatic antioxidants [19-20].  130 
When the balance for production vs. elimination of ROS and RNS is disrupted, the cell enters 131 
into an oxidative stress state, which will trigger the activation of some signalling cascades. One of the 132 
most important cell responses is mediated by nuclear factor-kB (NF-kB), a transcription factor that plays 133 
a crucial role in inflammation, immunity, cell proliferation, apoptosis and other cellular cycles.  134 
This transcription factor is normally maintained as inactive in the cytoplasm of non-stimulated cells by 135 
endogenous inhibitors, namely inhibitor of kB (I-kB). Under stress conditions, this transcription factor 136 
dissociates from its inhibitor and translocates to the nucleus, binding to DNA’s promoter or enhancer 137 
regions, causing an increase in the expression of several genes that in turn will promote the transcription 138 
of several pro-inflammatory cytokines and enzymes, resulting in an overall increment of oxidative stress 139 
[21]. In a similar way, the activation of mitogen activated protein kinases (MAPKs) signalling cascade, 140 
also triggered by oxidative stress conditions, causes dimerization of c-Jun and c-Fos into activator protein 141 
1 (AP-1) [21]. 142 
Hence, the overproduction of reactive species is settled in a vicious cycle way in oxidative stress 143 
conditions, since the high concentration of one reactive species stimulates further formation of ROS and 144 
RNS [17]. As an overall result, reactive species may cause damage in lipids, proteins, DNA and other 145 
macromolecules [16-17, 22], resulting in several pathological conditions [19].  146 
 147 
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2. ANTIOXIDANT PROPERTIES: STRUCTURE-FUNCTION RELATIONSHIPS 148 
In recent decades, a wide range of biological activities have been described for flavones [23], 149 
with particular emphasis on their antioxidant and protective ability on oxidative stress-related conditions. 150 
These capacities render flavones a great application in several fields, including the food, cosmetic and 151 
pharmaceutical industries, as well as in medicine [4].  152 
However, as referred before, the bioavailability of these compounds is still subject to debate, as this is 153 
influenced by many factors which are distinct in between different populations and even within the same 154 
population. Notwithstanding, it is presently accepted that once ingested, only a portion of low-molecular-155 
weight polyphenols may be readily absorbed in the small intestine, while 90-95% accumulate in the large 156 
intestinal lumen. Recent literature data also suggest that these non-absorbable compounds can be 157 
subjected to the enzymatic activities of the gut microbial flora and transformed into a series of absorbable 158 
low-molecular-weight phenolic metabolites [24-26]. 159 
Nonetheless, it is believed that flavones have both direct and indirect antioxidant properties. The 160 
direct effects include their ability to scavenge free radicals (e.g. superoxide anion radicals, hydroxyl 161 
radicals), to quench ROS (e.g. singlet oxygen) and to chelate metal ions and inhibit lipid peroxidation. In 162 
turn, the indirect effects of flavones are related to the modulation of the activity of key enzymes and/or 163 
interaction with receptors [27]. The main structural-fuction relationships elucidated so far, regarding the 164 
antioxidant abilities of flavones, are summarized below.  165 
 166 
 167 
2.1. Direct antioxidant effects 168 
 Similarly to other antioxidants, flavones counteract radicals mainly by two mechanisms, namely 169 
Hydrogen Atom Transfer (HAT) and by Single Electron Transfer (SET).  170 
As a result of an HAT reaction, an hydrogen atom is transferred from the flavone (FlOH) to the 171 
radical. The reaction between a flavone and a free radical results in a flavone phenoxyl radical (FlO
•
) and 172 
a stable substance (RH) (Eq 1a). The flavone phenoxyl radical formed could then react with other radicals 173 
((Eq 1b) R
• 
or (Eq 1c) FlO
•
) by radical-radical termination reactions, resulting in the formation of an 174 
unreactive compound i.e., (Eq 1b) FlO-R or (Eq 1c) FlO-OFl, respectively) [4, 28-30]. On the other hand, 175 
in a SET reaction, the flavone transfer one electron to reduce the radical, metals or carbonyls (Eq 2) [31]. 176 
 177 
Eq 1a. FlOH + R• → FlO• + RH 178 
Scavenging reaction 179 
 180 
Eq 1b. FlO• + R• → FlO-R 181 
Radical-radical coupling reaction 182 
 183 
Eq 1c. FlO• + FlO• → FlO-OFl 184 
Radical-radical coupling reaction 185 
 186 
Eq 2. FlOH + R• → FlOH• + R¯ 187 
Single-electron transfer reaction 188 
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 Note that HAT and SET mechanisms may occur in parallel, the main mechanism being 189 
determined by the structural properties of the antioxidant, together with pH, solubility, partition 190 
coefficient and system solvent [31]. At present, researchers believe that HAT is the most relevant 191 
mechanism to human biology [32-33]. 192 
 Generalistic methods for measuring radical scavenging capacity of antioxidants, in particular the 193 
chemical assays that use molecular probes e.g. trolox equivalent antioxidant capacity (TEAC), 2,2-194 
diphenyl-1-picrylhydrazyl radical (DPPH) scavenging capacity, ferric ion reducing antioxidant power 195 
(FRAP), oxygen radical absorbance capacity (ORAC) and trapping antioxidant parameter (TRAP), have 196 
also been extensively applied to flavones [15, 34]. With the exception of the last two, the remaining are 197 
simple methods to measure the ability of an oxidant to undergo single electron transfer reactions [32]. On 198 
the other hand, TRAP and ORAC assays evaluate the capability of an antioxidant to inhibit peroxyl 199 
radical-induced oxidations, through H-atom donation [32]. 200 
 The main structural features of flavones for conditioning their radical scavenging activity 201 
enclose (A) the 2,3-double bond in the C-ring in conjugation to 4-keto group in the C ring; (B) the ortho-202 
dihydroxy (catechol) group in the B-ring and (C) the presence of an hydroxyl group at position 5 (Fig. 3) 203 
[23, 35-36].  204 
 205 
 206 
 207 
Fig. (3). Major structural requirements for radical scavenging activity of flavones. 208 
 209 
 210 
 Notably, the 2, 3 double bond, in conjugation with the 4-keto group in the C-ring is responsible 211 
for the electronic delocalization starting from the B-ring [36], allowing the semiquinone radical to donate 212 
an electron and forming the stable-quinone structure, which is essential for SET mechanism. This 213 
capacity is improved by OH groups on the B-ring that decrease the O-H bond dissociation energy (BDE) 214 
and act as electron-donating groups [23]. 215 
 The catechol moiety on the B-ring confers high stability on the radical species through H-bond 216 
formation and also participates in electron delocalization, by increasing the electron density at the 217 
hydroxyl group and lowering the oxygenhydrogen bond energy [3, 27, 36]. The catechol group has been 218 
associated to the promotion of scavenging activity against peroxyl, superoxide and peroxynitrite radicals 219 
[30, 37]. Leopoldini and colleagues [36] showed that flavonoids with this dihydroxy functionality are the 220 
most active in donating an H atom while Rice-Evans et al. [38] concluded that this functionality 221 
contributes at about 25% for the antioxidant activity of luteolin (1) comparing to that of apigenin (2) and 222 
chrysin (3) (Fig. 4).   223 
 224 
A 
B 
C 
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Fig. (4). Chemical structures of flavones. The reference numbers for the compound structures are used 248 
throughout the manuscript. 249 
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 When present, the hydroxyl group at 5-position forms hydrogen bonds with the 4-keto group and 250 
in this condition the B-ring is slightly tilted with respect to the plane of A and C rings, thus facilitating the 251 
antioxidant action. The presence of additional OH group(s) on B-ring enhances its antioxidant action. 252 
Apigenin and luteolin are good candidates for the one-electron-transfer mechanism due to their planar 253 
conformation and the extended electronic delocalization between nearby rings [36]. 254 
 Besides the previous mentioned factors, some additional properties can be marked as 255 
conditioning factors for the the scavenging properties of flavones. E.g. the synergistic interaction between 256 
flavones and other physiological antioxidants such as ascorbate or tocopherol is described as important in 257 
improving the radical scavenging capacity of flavones [23]. Baicalein (4) is an example of this 258 
phenomenon. Albeit this flavone has low antioxidant capacity, it has been shown to have a good anti-259 
lipoxidation effect in 2,2′-azobis(2,4-dimethylvaleronitrile)-induced liposomal membranes, due to 260 
synergistic effects with beta-carotene [39]. 261 
 Chelating of metal ions such as the chelating of catalytically active metal (e.g. Cu (I), Fe (II) and 262 
Fe (III)) is also a relevant mechanism for the antioxidant activities of flavones with important role in 263 
cellular protection. The reaction of a phenoxyl radical and metal ions produces a radical anion that is the 264 
most stable structure.  265 
 Remarkably, the 5-hydroxyl group associated with the 4-keto and catecholic hydroxyl groups are 266 
extremely important to this capacity. In flavones, the metal-complexing sites are thought to occur 267 
between the hydroxyl at 5-position and the 4-keto group, as well as in between the ortho-hydroxyls on the 268 
B-ring (Fig. 5). Additionally, a study performed by Mira et al [40] indicated that the combined presence 269 
of 2,3-double bond (C-ring) and cathecol (B-ring) is an important feature for Fe
3+
 reducing activity while 270 
the cathecol group and the number of hydroxyl groups in A-ring plays a central role to Cu
2+ 
reducing 271 
activity [40-41]. 272 
 These reactions prevent the generation of oxidizing species (e.g. acting as initiators of lipid 273 
peroxidation or of the lipoxygenase reaction) and also highly reactive hydroxyl radicals that eventually 274 
could be formed by Fenton-type reactions [42]. 275 
 276 
 277 
Fig. (5). Possible sites for chelating the transition metal ions on flavones (adapted from [23]). 278 
 279 
 280 
2.2. Indirect antioxidant effects 281 
Xanthine oxidase (XO) is the unique enzyme for which structure-fuction relations have been 282 
partially clarified for flavones. This is a molybdoflavoprotein that is involved in the metabolism of 283 
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purines by catalyzing the conversion of hypoxanthine to xanthine and that of xanthine to uric acid (Fig. 284 
6), with the release of superoxide anion radical or hydrogen peroxide [43-45].  285 
 286 
 287 
 288 
Fig. (6). Conversion of hypoxanthine to xanthine and of xanthine to uric acid, by xanthine oxidase. 289 
 290 
 291 
 292 
In this regard, the inhibition of XO is very important because it prevents the production of 293 
excessive uric acid thus avoiding hyperuricemia, as well as the prevention of excessive levels of ROS 294 
[23]. Table 1 shows the IC50 values of distinct flavones for XO inhibiton. 295 
 296 
Table 1. IC50 values of distinct flavones for XO inhibition.    297 
 298 
Flavone IC50 (µM) Reference 
Apigenin 1/0.70 [46-47] 
Baicalein 2.79 [47] 
Chrysin 2.5/ 0.84 [46-47] 
Luteolin 0.75/0.55 [46-47] 
7, 3,4’-trihydroxyflavone  (5) 4 [46] 
7, 8, 3’, 4’-tetrahydroxyflavone (6) 10 [46] 
3’,4’-dihydroxyflavone (7) 40 [46] 
7-hydroxyflavone  (8) 40 [46] 
 299 
  300 
Rastelli and co-workers [48] proposed a model for flavones-xanthine oxidase interaction, based 301 
on similarities between the flavones and the substrates or inhibitors of the enzyme. Relevant points 302 
comprised (A) the matches of the negative electrostatic potential of oxygen in C-7 of flavones skeleton 303 
with that of the carbonyl group at C-6 in xanthine, due to the extended delocalization of negative charges 304 
over the entire benzo-pyrone structure; (B) the lone-pair minima of O-4 approaching the negative 305 
potential of N-3 and N-9 of hypoxanthine and xanthine, respectively; (C) the superimposition of 2-phenyl 306 
rings of flavones with the phenyl group of the most potent purine inhibitors of the enzyme (as a 307 
consequence of the carbonyl superimposition, a group that is essential for activity), thus suggesting that 2-308 
phenyl ring is responsible for hydrophobic interactions with the XO in the same location as the inhibitors; 309 
(D) the presence of a substituent at C-4’ (in addition to an hydroxyl group at C-7) enhanced the flavone´s 310 
activity mainly because it is involved in dispersion interactions with XO. Notably, the presence of a 311 
hydroxyl group at C-7 is established as fundamental to the inhibitory effect of flavones on XO, mainly 312 
because this is responsible for the binding of flavone to the active site of the enzyme and it has a low pKa 313 
thus ensuring that there is enough dissociated form at physiological pH. Moreover, this group allows 314 
hydrophobic interactions between the flavone and XO [23, 48]. 315 
From experimental and theoretical results obtained more recently, several authors concluded that 316 
along with the mentioned factors, the substitution of hydroxyl groups at 5- and 7-positions, as well as the 317 
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substitution of a catechol or a 3’,4’,5’-pyrogallol functionality, are also structurally important factors 318 
contributing to the inhibition of XO by flavones [23, 47].  319 
 Notwithstanding, there are already some findings of the structure-activity relation between 320 
flavones and other enzymes such as iNOS. In the investigation of Kim et al. (1999), the authors have 321 
concluded that the most active flavonoids inhibiting the iNOS were those containing a C-2,3 double bond 322 
(such as in flavones) and 5,7-dihydroxyl groups in the A-ring. Furthermore, the substitution of hydroxyl 323 
groups at 4’- or 3’,4’- in the B-ring (apigenin and luteolin, respectively) may contribute to the inhibitory 324 
effect on iNOS [49-50]. 325 
 Moreover, evidence points to these same structural features are related to the capacity of 326 
attenuating MAPKs signaling by interfering with c-Fos, and c-Jun gene expression expressions and AP-1 327 
transcriptional activity, as well as interfering with IkB kinases (IKK)/NF-kB pathaway [51]. 328 
 329 
 330 
3. ROLES OF FLAVONES IN OXIDATIVE STRESS-RELATED DISEASES 331 
Oxidative stress, i.e., the physiological condition arising from imbalance between the rates of 332 
production and release of free radicals, is closely associated to several diseases including cancer, diabetes, 333 
osteoporosis, neurodegenerative and cardiovascular diseases and many other aging-associated disorders 334 
[52]. 335 
 In opposition, diet-derived antioxidants (including flavones) are regarded as potential protective 336 
agents in oxidative stress-related diseases. In fact, recent studies have demonstrated promising results 337 
regarding to the protective effects of flavonoids and/or flavones against stress-related diseases, both in 338 
vitro and in vivo models of diseases. Epidemiological studies and meta-analyses also suggest an inverse 339 
relationship between the consumption of flavonoid-rich diets and the development of distinct age-related 340 
diseases [53-55]. Still, despite these evidences, it should be remarked that the mechanisms underlying the 341 
protective effects of most flavonoids and/or flavones remain unclear and hence, there is a great demand 342 
on structure-activity studies on this area. Amongst the several oxidative-stress related disorders, the 343 
beneficial effects of flavones discussed below will be focused on the most relevant data reported on 344 
literature for flavones i.e., those correlated with neurodegenerative disorders, diabetes and its associated 345 
complications and with coronary heart diseases. 346 
 347 
 348 
3.1. Neurodegenerative disorders 349 
 The brain is responsible for 20% of the total oxygen consumption due to its high metabolic 350 
requirements. Thus, this organ is characterized by high activity of the mitochondrial electron transport 351 
chain and high ROS production ratios [56]. The combination of those factors with weak tissue 352 
regeneration makes the brain one of the most susceptible organs to the oxidative stress [16]. In cerebral 353 
pathophysiologic conditions, oxidative damage occurs in proteins, lipids, DNA and takes place in 354 
modulation of apoptosis and necrosis [13]. Moreover excitotoxicity, mitochondrial dysfunction and intra 355 
or extracellular protein aggregation also contribute for the increment of oxidative stress and neuronal 356 
deregulation and death [57]. Hence, overall, oxidative stress is considered to be the major cause of the 357 
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neuronal loss occurring in chronic neurodegenerative diseases such as Alzheimer, Parkinson and 358 
Huntington [58], as well as in acute insults (ischemic and hemorrhagic stroke). In turn, reported data 359 
suggest that flavones can exert important protective roles in several models of neurological diseases 360 
(Table 2). 361 
 Cerebral ischemia results from a transient or permanent reduction in cerebral blood flow that is 362 
restricted to the territory of a major brain artery, during which a series of phenomena such as 363 
excitotoxicity, oxidative stress, inflammation and apoptosis occur [59]. 364 
In their study, Zhao et al. [60] used the ischemic/ reperfusion (I/R) rat model to investigate the anti-365 
ischemic potential of luteolin. The intraperitoneal injection of the encapsulated flavone upon I/R, for a 366 
period of 13 days, caused a noteworthy dose-dependent prevention of the induced injuries, due to the 367 
capacity of luteolin in reducing the increasedmitochondrial ROS levels as well as enhancing the activity 368 
of GSH and CAT. 369 
Quiao and co-workers [61] additionally showed that luteolin is able to counteract diret and indirect 370 
oxidative stress events on I/R model. In more detail, the authors showed that this flavone could 371 
significantly stimulate the activity of the two antioxidant enzymes CAT and SOD-1 and overall decreased 372 
the oxidative stress marker malondialdehyde (MDA). The treatment also induced a decrease on the levels 373 
of the proapoptotic protein Bax and raised those of the anti-apoptotic protein Bcl-2. These results were 374 
reinforced by Zhang et al. [62], who reported that oral administration of luteolin (4 mg/kg) inhibited the 375 
neuronal death in a similar I/R model, suggesting that its neuroprotective action was not only due to its 376 
antioxidant properties but also to its capacity to induce nuclear factor erythroid-derived 2-like 2 (Nrf2) 377 
activity. In turn, this theory was recently supported by Xu et al. [63] who have demonstrated in traumatic 378 
brain injury cultured mice neurons that, besides restoring the levels of MDA and glutathione peroxidade 379 
(GSH-px), luteolin (at 10-50 μM ) could enhance the Nrf2 translocation to the nucleus and subsequently 380 
caused the up-regulation of its downstream products, concomitantly lowering the intracellular ROS levels 381 
and increasing neuron survival. 382 
 Luteolin derivatives, either natural or synthetic, have also been suggested as potential agents in 383 
prevention and/or treatment of diverse neurological disorders. E.g. in a Parkinson disease model, 384 
cynaroside (luteolin-7-O-β-ᴅ-glucopyranoside) (9) has been shown to efficiently scavenge ROS-related 385 
products and to increment GSH levels, as well as to reduce the activities of the pro-aptotic caspase-3 and -386 
8, thus protecting the cells from oxidative stress and promoting their viability [58]. The neuroprotective 387 
activity of this flavone on the same cellular model has been recently reaffirmed [64].  388 
 In turn, two synthetic 3-alkyl-luteolin derivatives bearing alkyl chains of 4 (10) and 6 (11) 389 
carbons (at 10-25 μM) were shown to rescue the intracellular ROS generation and caspase-3-like activity 390 
in striatal cells derived from Huntington disease knock-in mice, expressing mutant huntingtin [65].  391 
 Besides luteolin and/or luteolin derivatives, other flavones have already been tested in distinct 392 
models of neurological diseases. In hippocampal cells, the treatment with apigenin (at 5-60 μM) inhibited 393 
kainic acid-induced excitotoxicity (analogous of glutamate) in a dose-dependent manner, decreasing the 394 
intracellular ROS generation and increasing the GSH levels, hence demonstrating its neuroprotective 395 
potential [66]. Moreover, the treatment of cooper-stimulated APPsw cells (i.e., a model of Alzheimer 396 
disease manifested by an overexpression of amyloid precursor protein (APP) and a severe redox 397 
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imbalance) with apigenin (at 0.1-10 μM) resulted in a dose-dependent reduction of ROS levels and an 398 
enhancement of SOD and GSH-px activities. The authors also reported that the treatment with this 399 
flavone blocked the ROS-induced MAPK (mitogen-activated protein kinase) signaling pathways, 400 
preserved mitochondrial function and regulated apoptosis [67]. 401 
In addition, the oral administration of 10-20 mg/kg of apigenin to mice in vivo in a model of Alzheimer's 402 
disease caused the reduction of oxidized hydroethidine (a representant of superoxide anion levels on the 403 
cerebral cortex) in the brain when compared to those of untreated mice [68]. Recently, identical results 404 
were obtained by Zhao et al. [69], who additionally reported an enhanced SOD and GSH-px activities 405 
induced by apigenin, with respect to those observed in the control mice.  406 
 Scutellarein (12) and/or its derivatives, which are naturally found in Scutellaria plants, are also 407 
promising neuroprotective agents. In particular, Liu et al. [70] have shown that the treatment of H2O2-408 
induced primary cultures of rat neuronal cells with scutellarin (scutellarein-7-glucuronide) (13) for 10-409 
100 μM, caused a significant dose-dependent decrease on the MDA and NO• levels, also enhancing the 410 
cells viability with respect to controls. Further analysis lead the authors to conclude that the decrement of 411 
intracellular NO
•
 levels was resultant from the scutellarin´s capacity in inhibiting the neuronal NOS 412 
activity.  413 
 In turn, Hu et al. [71] reported that scutellarin caused up-regulation of eNOS and down-414 
regulation of iNOS, as well as of vascular endothelium growth factor and of basic fibroblast growth factor 415 
(VEGF and bFGF, respectively), overall preventing the cerebral injury caused by I/R on Sprague-Dawley 416 
rats. In addition, further research revealed that the levels of SOD, CAT and GSH were significantly 417 
increased in ischemic brain tissues of scutellarin-treated rats, enhancing the endogenous antioxidant 418 
activity. Moreover, the addition of sculletarin to an in vitro neuron culture under an oxygen and glucose 419 
deprivation treatment, inhibited the levels of ROS generation and decreased the percentage of apoptotic 420 
cells [72]. 421 
Protective effects of scutellarin have also been suggested against Alzheimer´s disease since the 422 
treatment of Aβ-treated rat brains with this flavone induced the simultaneous increase of SOD´s activity 423 
and the decrease on MAO´s (monoamine oxidase) activity. The treatment also diminished the levels of 424 
inflammatory cytokines, hence overall lowering the oxidative stress and inflammation events, and 425 
resulting in an effective amelioration of the memory and learning abilities of the rats [73]. 426 
 Despite the majority of experiments were performed with the glycosidic form of the flavone (i.e. 427 
scutellarin), it is important to highlight that the main the main in vivo metabolite of this flavone, i.e. 428 
scutellarein, has been demonstrated to exhibit stronger antioxidant capacities and to further protect PC12 429 
cells against H2O2-induced cytotoxicity than its glycoside scutellarin [74]. Similar results were obtained 430 
for the neuroprotective effects of these two flavones on a cerebral I/R model, suggesting that scutellarein 431 
is preferential for therapeutical effects [75]. 432 
Another flavone, the O-methylated flavone nobiletin (14) isolated from citrus peels, has been shown to be 433 
able to counteract oxidative stress events in H2O2-induced PC12 cells [76]. The exposure of these cells to 434 
the flavone at 3-25 μM induced a dose-dependent increase on SOD and GSH activities, the decrease of 435 
MDA levels and lipid peroxidation, together with the regulation of mitochondrial membrane potential and 436 
the inhibition of caspase-3 activity [76]. Moreover, the treatment of senescence accelerated mice 437 
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(SAMP8) with this flavone (10 - 50 mg/kg) was also able to restore the glutathione derivatives 438 
GSH/GSSG ration, increasing the GSHpx and SOD activities and reducing the phosphorylation of tau 439 
protein in the hippocampus of the mouse brain, which lead to the restoration of learning and memory 440 
deficits, typical symptoms of Alzheimer’s disease [77]. 441 
Overall, these results suggest that flavones (in particular those that are found in natural food sources) are 442 
potential candidates to be used in the intervention for neurodegenerative diseases, either in a preventive 443 
manner or as a possible therapy. 444 
 445 
Table 2. Protective effect of flavones on neurodegenerative disorders.    446 
 447 
Compound Model Test Conditions Effects Ref 
Luteolin 
I/R rat model 
5 and 20 mg/kg/day 
for 13 days, 
intraperitoneal 
injection 
↓ behavioural deficit scores; ↓ infarct volume; ↑ CAT levels; ↓ 
GSH levels; ↓ ROS production on hippocampus, frontal 
cortex and striatum 
[60] 
I/R rat model 10 and 25 mg/kg 
↓ neurological deficits score; ↓ infarct volume; ↓ Bax 
protein/mRNA levels; ↑ Bcl-2 and claudin-5 protein/mRNA 
levels; ↑ SOD-1/CAT; ↓ MDA levels 
[61] 
SH-SYS cell 
2-50 µM prior to 
treatment with 200, 
500 or 800 µM H2O2 
↑ Nrf2/HO-1 expression levels; ↓ H2O2-induced cell death; ↓ 
ROS production 
[62] 
I/R rat model 
4 mg/Kg , tail vein 
injection 
↓infarct area; ↓caspase-3 cleavage [62] 
TBI mice; 
mouse 
neurons 
10, 30 and 50 mg/kg , 
intraperitoneal 
injection 
↑ motor performance; ↓ apoptotic index; ↓ MDA levels; ↑ 
GPx expression; ↑ Nrf2 translocation to nucleus; ↑ Nrf2-
AREs binding; ↑ Nrf2 downstream proteins; ↓ intracellular 
ROS production and TBI-induced cell damage 
[63] 
Luteolin-7-O- 
[58] 
β-D- 
glucopyranoside 
PC12 cell 
25-100 µM for 6h 
prior 6-OHDA (175 
µM), H2O2 (87.5 µM) 
and 6-OHDA (175 
µM) + CAT (87.5 U) 
(p-quinone) treatment 
↓ p-quinone- and H2O2-induced cell death; ↓ ROS production; 
↓ caspase-3 and -8 levels; ↓ OH radicals; ↑ GSH levels 
[58] 
PC12 cell 
100 µM for 6h prior 
6-OHDA (175 µM) 
treatment 
↓6-OHDA-induced neurotoxicity [64] 
3-alkyl-luteolin 
STHdh7/7 and 
STHdh111/111 
cell lines 
10-25 µM ↓ intracellular ROS levels; ↓ caspase-3 activity [65] 
Apigenin 
Hippocampal 
cells 
5-60 µM 0.5-1h 
before KA (100 µM) 
↓KA-induced neurotoxicity; ↓ROS production 
[66] 
ICR mice 
25-50 mg/kg followed 
by KA (40 mg/kg), 
intraperitoneal 
injection 
↓ behaviour and electrical seizures induced by KA; ↓ GSH 
depletion on convulsive mice; ↓ KA-induced neuronal damage 
on hippocampal CA3 regions 
APPsw cells 
0.1-10 µM prior to a 
24h 200 µM Cu 
incubation 
↓ Cu-induced cell death; ↓ APP expression and Aβ1-42 
secretion; ↓ ROS generation; ↑ GSH levels; ↑ intracellular 
SOD and GPx levels; ↓ mitochondrial dysfunction; ↓ cyt c 
release; ↓ nuclear condensation; ↓ p38 MAPK-MK2-Hsp27 
and SAPK/JNK-c-Jun pathways; ↓ caspase-3 and -9 activity 
[67] 
APP/PS-1 
mice 
40 mg/kg/day for 5 
days, oral 
administration 
↓ spatial learning and memory impairment; ↓ Aβ burden by 
decreasing Aβ1-40 and Aβ1-42 insoluble forms; ↓ BACE-1 
levels; ↓ OHEt signals; ↑ SOD and GSH levels; ↑ BDNF, p-
ERK1/2 and CREB expression on cerebral cortex 
[69] 
Aβ25-35-
induced 
amnesia 
mice models 
10  and 20 mg/kg/day 
for 8 days, oral 
administration 
Ameliorates spatial learning and memory deficits; protects 
microvessels integrity and attenuate neuronal loss; ↓ OHEt 
signals on cytosol and neurovascular interface; ↑occuldin, ZO-
1 and claudin-5 levels; ↓ AChE activity; ↑ BDNF/ACh levels; 
↑TrkB and pCREB expression on cerebral cortex 
[68] 
Scutellarein 
Neuronal 
cells 
10-100 µM prior to 2 
mM H2O2 exposure 
↓ NO release; ↓ cNOS activity; ↓ MDA levels; ↓ H2O2-
induced cell death 
[70] 
I/R rat model 
25-75 mg/kg/day for 
7 days, intragastric 
injection 
↓ infarct area; ↓ neurological score; ↓ BBB permeability; ↓ 
NOx production ; ↑ eNOS expression;↓ bFGF/VEGF/iNOS 
expression 
[71] 
I/R rat model 
20-60 mg/kg, 
intraperitoneal 
injection 
↓ neurological scores; ↓ infarct area; ↑ SOD/CAT activity; ↑ 
GSH activity 
[72] 
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cortical 
neurons 
25-100 µM on a OGD 
system 
↓ LDH release; ↓ apoptotic cells; ↓ ROS generation 
Rats with 
Aβ25-35 
aggregates 
10 mg/day for 20 
days, intragastric 
injection 
Ameliorates learning and memory dysfunction associated with 
Aβ aggregates; ↑ SOD activity;↓ MAO activity; ↓ IL-1β/IL-6/ 
TNF-α; ↓ apoptotic neurons 
[73] 
PC12 cell 
line 
1-100 µM co 
incubated with 400 
µM H2O2, pre 
incubated for 30 min 
and pre incubated for 
3h before H2O2 
↓ H2O2-induced cell death [74] 
I/R rat model 
25-100 mg/kg, 
intragastic injection 
↑ neurological score; ↓ infarct area [75] 
Scutellarein 
SAMP8 
mice 
10-50 mg/kg, 
intraperitoneal 
injection 
↓ cell death; ↓ LDH leakage; ↓ MDA levels; ↑ GSH and SOD 
expression levels; ↑ mmp; ↓ ROS generation; ↓ caspase-3 
activity 
[76] 
Nobiletin 
SAMP8 
mice 
10-50 mg/kg, 
intraperitoneal 
injection 
Reversed recognition memory and context-dependent fear 
memory impairment; ↑ Mn-SOD at 50 mg/kg in striatum and 
GPx in cerebral cortex, hippocampus and striatum; ↓ the 
GSH/GSSG ratio loss in cerebral cortex, hippocampus, 
striatum and cerebellum; ↓ protein carbonyl levels in cerebral 
cortex and hippocampus; ↓ tau protein hyperphosphorylation 
[77] 
6-OHDA – 6-hydroxydopamine; ACh – acetylcholine; AChE – acetylcholinesterase; Api – apigenin;  APP – amyloid protein precursor;  APPsw – 448 
swedish mutant APP; ARE – antioxidant response element;  BACE-1 – β site APP-cleaving enzyme; BBB – blood brain barrier; BDNF – brain-derived 449 
neurotrophic factor; bFGF- basic fibroblast growth factor; CAT – catalase; cNOS – constitutive nitric oxide synthase;  CREB – cAMP response 450 
element-binding protein; eNOS – endothelial nitric oxide synthase;  ERK1/2 – extracellular signal-regulated kinase; GPx – glutathione peroxidase; 451 
GSH – reduced glutathione; Hsp27 – heat shock protein 27; I/R – ischemia/reperfusion; iNOS – inducible nitric oxide synthase; KA – kainic acid; 452 
LDH – lactate dehydrogenase; Lut – luteolin; MAO – monoamine oxidase; MAPK – mitogen activated protein kinase; MDA – malondialdehyde;  453 
MK2 – MAPKAP kinase 2; mmp – mitochondrial membrane potential; Nar – naringin; Nob – nobiletin; Nrf2 – nuclear factor erythroid 2-related factor 454 
2; OHEt – oxidized hydroethidine; PC12 – rat pheochromocytoma cell line; PS-1 – presenilin-1; ROS – reactive oxygen species; SAMP-8 – 455 
senescence-accelerated mouse prone 8; Scut – scutelarin; SH-SYS – human derived neuroblastoma cells; SOD – superoxide dismutase; STHdh7/7/111/111 456 
– striatal cells expressing normal huntingtin/mutant huntingtin; TBI – traumatic brain injury; TrkB – tropomyosin related kinase B;  VEGF – vascular 457 
endothelial growth factor; ZO-1 – zona occuldens protein-1 458 
 459 
3.2. Diabetes and associated complications 460 
Increasing evidence in both experimental and clinical studies suggests that oxidative stress plays 461 
a major role in the pathogenesis of both types of diabetes mellitus. Free radicals are formed 462 
disproportionately in diabetes due to glucose oxidation, non-enzymatic glycosylation of proteins and the 463 
subsequent oxidative degradation of glycated proteins. The abnormal high levels of free radicals and the 464 
simultaneous decline of antioxidant defense mechanisms can result in the damage of cellular organelles 465 
and enzymes, increased lipid peroxidation and development of insulin resistance. These consequences of 466 
oxidative stress promote the development of other diabetes-associated complications [78]. 467 
Table 3 resumes relevant reported data for the protective effects of flavones on diabetes and diabetes-468 
associated diseases. 469 
Pancreatic β-cells are known to be particularly sensitive to oxidative stress, a fact that may 470 
contribute to the impaired β-cell function that is characteristic of diabetes. The pre-treatment of H2O2-471 
stimulated pancreatic βTC1 cells with chrysin, quercetin or catechin (all at 50 μM) has been found to 472 
significantly protect the cells against the generated oxidative stress. Interestingly, despite being the most 473 
hydrophobic of the three flavonoids and lacking the hydroxyl group on the B-ring (which increases 474 
antioxidant activity), chrysin was the compound that conferred better protection to the cells [79].  475 
 Reducing sugars (e.g. glucose and 2-deoxy-ᴅ-ribose) produce ROS through autoxidation and 476 
protein glycosylation, hence contributing for progressive β-cell failure. In this context, Suh and co-477 
workers [80] have demonstrated that apigenin conferred protection on 2-deoxy-ᴅ-ribose-induced HIT-15 478 
pancreatic cells through regulation of the mithocondrial membrane potential, as well as through 479 
decrement of intracellular ROS levels. A previous study have also demonstrated that apigenin and luteolin 480 
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could protect RINm5F rat insulinoma cells from interleukine (IL)-1β- and interferon (IFN)-γ-induced 481 
damage, since they inhibit NO
• 
production, mainly by reducing the iNOS mRNA and protein expression, 482 
apparently through the inhibition of nuclear factor-κB (NF-κB) activation [81]. 483 
More recently, some flavonoid components from extracts of Gelam honey, including luteolin and 484 
chrysin, were tested on high glucose-stimulated HIT-15 pancreatic cells. The pretreatment of cells with 485 
these flavones prior to culturing in a high glucose level medium resulted in a significant dosedependent 486 
decrease of the intracellular ROS generation, along with those of MDA and of glucose-induced lipid 487 
peroxidation, which lead to the general enhancement of the cells insulin contents and their viability [82]. 488 
As the metabolic disorder progresses, defects in glucose metabolizing machinery restrains the 489 
physiological system from correcting the imbalance in glucose levels, thus resulting in chronic 490 
hyperglycemia, which in turn is associated with long-term complications such as retinopathy, 491 
nephropathy, neuropathy, cardiomyopathy among other complications [83-84]. 492 
In a streptozotocin-nicotinamide (STZ-NA)-induced diabetic rats, Srinivasan and Pari [84] tested 493 
the protective effect of diosmin (15) against consequent oxidative stress damage. After a period of 45 494 
days of oral administration of diosmin (100 mg/kg/day), these rats had their plasma levels of glucose 495 
decreased and those of insulin increased. Furthermore, on these same diosmin treated rats, increased 496 
activity of the antioxidant enzymes SOD, CAT, GSH-px, glutathione-S-transferase (GST) and levels of 497 
non-enzymatic antioxidants vitamin C, vitamin E and GSH were observed, along with decreased levels of 498 
lipid peroxidation markers in kidney and liver tissues. Chrysin has also been suggested to display 499 
hepatoprotective properties, since it was able to reduce the levels of MDA and lipid peroxidation in liver 500 
of alloxan-induced diabetic mice [85]. 501 
 502 
In addition, luteolin has already been shown to display positive results in protection against 503 
nephropathy (diabetesassociated kidney disorders). This flavone was introduced (200mg/kg) in the diet of 504 
Sprague-Dawley rats, after 48h of STZ-diabetes induction. The gathered data confirmed that upon 8 505 
weeks of treatment, the blood glucose levels of luteolin- treated rats was significantly reduced in 506 
comparison to that of controls. The authors also reported that levels of MDA on the kidneys of the 507 
luteolin-treated rats was signifycantly lowered, while the levels of SOD and the phosphorylation of 508 
Akt/PKB (serine/threonine-specific protein kinase) were significantly increased, evidencing the protective 509 
effects of luteolin against diabetic nephropathy [86]. 510 
Besides protection on kidneys disorders, luteolin has been suggested as a promising protective 511 
agent against diabetic-associated cardiomyopathy. Quian et al. [87] showed that the treatment of diabetic-512 
Sprague–Dawley rats with luteolin revealed a marked attenuation of the endothelium-dependent 513 
relaxation impairment, as well as the strong reversion of the increased ROS levels and OH
●–
 formation, 514 
together with decreased NO
•
 levels and NOS and SOD activities. In addition, rats fed with this flavone 515 
(200 mg/kg) before the induction of diabetes-stimulus were demonstrated to have lower levels of MDA, 516 
lactate dehydrogenase (LDH) and LDL cholesterol, and increased levels of HDL cholesterol, SOD and 517 
Akt phosphorylation, with respect to the controls [88]. 518 
Luteolin also show positive results in diabetic-associated neuropathy. According to the work of Liu et al. 519 
[83], the administration of luteolin (50-100 mg/kg) for a period of 8 weeks to Sprague-Dawley rats upon 520 
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the STZinduction of diabetes, resulted in the decrement of cerebral MDA and lipid peroxidation levels, 521 
while the levels of GSH, SOD and CAT were substantially increased, resulting in effective counteraction 522 
of the neuronal damage and cognitive dysfunction. Besides luteolin, both chrysin and diosmetin (16) have 523 
also been suggested as protective agents in diabetic neuropathy. In fact, male Wistar rats treated with 524 
chrysin after diabetes induction have improved their cognitive deficits [89]. These effects were related not 525 
only to the reduction of the MDA levels and an increase of SOD, CAT and GSH levels, thus relieving the 526 
oxidative stress, but also to the suppression of the p65 subunit of NF-κB, IL-1β an IL-6 activities, which 527 
prevented the inflammation process. In turn, diosmin has shown its potential in preventing the 528 
progression of early diabetic neuropathy in rats. Type-2 diabetes was induced on Sprague-Dawley rats 529 
and this was followed by the oral administration of diosmin (50 and 100 mg/kg/day) for 4 weeks. After 530 
treatment with the flavone, the elevated blood sugar and lipid profiles were restored, together with those 531 
of the increased levels of MDA and NO
•
, and the decreased levels of SOD and GSH. Overall, this 532 
treatment with diosmin resulted in alleviation of thermal hyperalgesia, cold allodynia and walking 533 
function of the diabetic rats [90]. 534 
Taking all this data into account, it is pertinent to say that flavones have shown promising results that 535 
could make them potentially useful for the development of future therapies to treat and/or prevent  536 
diabetes and diabetes-associated complications. 537 
 538 
Table 3. Protective effect of flavones on diabetes and diabetes-associated diseases.    539 
Compound Model Test conditions Effects Ref 
Apigenin HIT-T15 cell line 
0.01-10 µM apigenin 
for 30min prior to 
dRib 30 µM for 24h 
↑ cell survivability; ↓ apoptosis, ROS generation and loss of 
mmp; ↓ NFkB and AP-1 expression 
[80] 
Apigenin, 
Luteolin 
RINm5F 
IL-1β- and IFN-γ-
induced oxidative 
stress 
↓cytotoxicity; ↓ NO production; ↓ iNOS mRNA/protein 
levels; Inhibits NFkB binding activity and IkBα degradation 
on cytosol; ↓ p50 and p65 content on nucleus; ↑ insulin 
secretion 
[81] 
Chrysin 
HIT-T15 cell line 
50 µM + Mb 30 µM 
for 24h prior to 
GO/metMb for 20h 
↓ damage of H2O2/metMb-induced oxidative stress [79] 
STZ-induced 
diabetic rats 
30 and 100 mg/kg, 
intraperitoneal 
injection 
↓ Glucose; Alleviates diabetes-associated cognitive deficits; 
↓ MDA, p65 of NFkB, TNF-α, IL-1β and IL-6 content and 
caspase-3 activity; ↑ SOD, CAT and GSH levels 
[89] 
Alloxan-induced 
diabetic mice 
50 mg/kg, 
intraperitoneal 
injection 
↓ MDA levels [85] 
Chrysin, 
Luteolin 
HIT-T15 cell line 
20-80 µM for 24h 
prior to a 24h 
incubation with 20 
or 50 mM glucose 
Protected cells from glucose-induced damage; ↓ ROS 
generation; ↓ MDA levels; ↓ F2 isoprostane content; ↑ 
insulin content 
[82] 
Diosmin 
STZ-induced 
diabetic rats 
100 mg/kg, 
intragastric injection 
↑ Plasma insulin; ↓ plasma glucose; ↓ 
TBARS/hydroperoxides; ↑ SOD; ↑ CAT/GST; ↑ GPx; ↑ GR; 
↑ Vit. C/Vit. E/GSH; ↓ GSSG; ↑ GSH/GSSG ratio 
[84] 
STZ and high fat 
diet-induced 
diabetic rats 
50 and 100 mg/kg, 
oral administration 
↓ Glucose; ↓ TC/TG; ↑TP; ↓ thermal hyperalgesia and cold 
allodynia; ameliorates on walking function test; ↓ MDA 
levels; ↑ GSH/SOD levels; ↓ NO• generation 
[90] 
Luteolin 
STZ-induced 
diabetic rats 
200 mg/kg, 
intragastric injection 
↓ Glucose/BUN/Creatinine/TC/TG/LDL levels; ↑ HDL 
levels; ↓ 24h urea protein; ↓ TC/TG; ↓ SOD activity; ↓ MDA 
levels; ↑ HO-1 expression; ↑ Akt/Pkb phosphorylation 
[86] 
HG-mediated 
impairment of 
endothelium 
0.5-90 µM with 44 
mM glucose 
↑ Endothelium-dependent vasorelaxation; ↓ ROS; ↓ OH; ↑ 
SOD/cNOS; ↓ iNOS; ↑ NO• levels 
[87] 
STZ-induced 
diabetic rats 
10 , 50 and 100 
mg/kg/day for 8 days 
↑ Endothelium-dependent vasorelaxation 
STZ-induced 
diabetic rats 
200 mg/kg, oral 
administration 
↓ CK/LDH; ↓ TC/TG/LDL levels; ↑ HDL levels; ↓ MDA 
levels; ↑ SOD levels; ↑ HO-1 levels; ↑ Akt/Pkb levels; ↓ 
CTGF levels 
[88] 
STZ-induced 
diabetic rats 
50 and 100 mg/kg, 
oral administration 
↓Glucose; ↓ diabetes-associated cognitive decline; ↓ ChE 
activity; ↓ MDA levels; ↑ GSH levels; ↑ SOD/CAT activity 
[83] 
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AP-1 – activator protein-1; Api – apigenin; CAT – catalase; ChE – cholinesterase; Chr – chrysin; CK – creatine kinase; cNOS – constitutive nitric 540 
oxide synthase; DS – diosmin; dRiB – 2-deoxy-D-ribose; GO – glucose oxidase; GPx – glutathione peroxidase; GR – glutathione reductase; GSH – 541 
reduced glutathione; GST – glutathione-S-transferase; HDL – high density lipoprotein; HG – high glucose; HIT-T15 – insulin-secreting hamster β-542 
cells; HO-1 – hemeoxygenase-1; IFN-γ – interferon-γ; IL-1β – interleukin-1β; IL-6 – interleukin-6; iNOS – inducible nitric oxide synthase; LDH – 543 
lactate dehydrogenase; LDL – low density lipoprotein; Lut – luteolin; Mb – myoblobin; MDA – malondialdehyde; metMb – metmyoglobin; mmp – 544 
mitochondrial membrane potential; NF-kB – nuclear factor-kappa B; ROS – reactive oxygen species; RINm5F – rat insulinoma cell line; SOD – 545 
superoxide dismutase; STZ – streptozotocin; TBARS – thiobarbituric acid reactive substances; TC – total cholesterol; TG – total triacylglycerol 546 
3.3. Coronary heart diseases 547 
 Atherosclerosis (AS) i.e., the main cause of cardiovascular diseases (CVD), has also been closely 548 
associated to oxidative stress events. In fact, high levels of ROS are known to generate an increment of 549 
the oxidative stress in the vessel wall, as well as to promote the oxidation of the serum lowdensity 550 
lipoprotein (LDL) cholesterol, being the latter recognized as the major cause of AS and other 551 
cardiovascular diseases [91-92]. Elicitation of endothelial cells by the oxidized LDL (oxLDL) and other 552 
factors further stimulate the intracellular production of ROS, which in turn act as key second messengers, 553 
being responsible for initiating a series of intracellular signaling pathways [93]. In particular, the injured 554 
cells start expressing cellular adhesion molecules (CAMs) that promote the binding and recruitment of 555 
circulating leukocytes. These immune cells engulf oxLDLs and consequently form the foam cells that 556 
migrate to the intimal layer of the vessel where they further stimulate inflammatory mediators (including 557 
cytokines, chemokines and NO
•
), contributing to additional increment of the oxidative stress [94]. 558 
 Several authors have reported protective effects of flavones against coronary heart diseases 559 
(Table 4). Yi et al. [95] tested several flavonoids including flavone (17), chrysin, apigenin, luteolin, 6-560 
hydroxyflavone (18), baicalein and 7-hydroxyflavone on oxLDL-induced human umbilical vein 561 
EA.hy926 cells, in order to assess their protective potential on AS. Among the tested flavones, the authors 562 
concluded that the treatment with apigenin and luteolin (at 40 μM) promoted NO• release, suggesting a 563 
particular effect of the two flavones on the endothelial secretory function and endothelium-dependent 564 
vasorelaxation. Other positive effects of the apigenin and luteolin included the inhibition of MDA and 565 
ICAM-1 and cell viability amelioration. Further investigation performed in a similar cellular model 566 
corroborated that apigenin and luteolin (80 μM) could maintain the cell viability, as well as regulate 567 
intracellular ROS production [96]. The authors also observed that the two flavones had a notable 568 
inhibitory effect on the oxLDL-induced p38MAPK phosphorylation and NF-κB (p65) translocation to the 569 
nucleus, together with a deep reduction on the mRNA expression of several NF-κB-mediated genes, 570 
hence blocking the generation of more ROS. 571 
When the inflammatory endothelial response is settled, TNF-α, a key cytokine in inflammation is 572 
released. This cytokine has a multifunctional role via the activation of numerous intracellular signaling 573 
pathways, including MAPK and transcription of NF-κB that in turn will stimulate the production of more 574 
cytokines (including itself) and increase ROS formation, resulting in a vicious cycle [94]. In order to 575 
evaluate luteolin capacity to counteract the effects of TNF- α, Xia et al. [97] tested the human umbilical 576 
endothelium cells’ (HUVEC) response in presence/absence of the flavone. The treatment with luteolin 577 
(6.25-25 μM) was able to suppress the TNF- α -induced ROS generation, as well as the expression of the 578 
superoxide producing enzyme NADPH oxidase-4 and its subunit p22phox. The flavone also suppressed 579 
the expression of ICAM and VCAM, caspase-3 and -9, and enhanced Bcl-2, consequently ameliorating 580 
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the cells viability. Finally, the treatment with luteolin could inhibit transcriptional activity of NF-kB, and 581 
p38 and ERK 1/2 phosphorilation, overall attenuating oxidative stress and inflammatory processes. 582 
 583 
One of the main complications of atherosclerosis is the acute myocardial infarction (AMI) [98-99]. This 584 
is characterized by the interruption of blood supply (ischemia) to a part of the heart. Ischemia and ensuing 585 
oxygen shortage induce myocardium the death of heart cells, thus, reperfusion therapy must be applied as 586 
soon as possible in order to attenuate the ischemic injury [100]. Luteolin has also demonstrated potential 587 
in the prevention of ischemic-associated oxidative stress. In Sprague-Dawley rats subjected to myocardial 588 
ischemia/reperfusion, luteolin significantly reduced myocardial infarct size, as well as MDA production 589 
in the injured tissue samples. Moreover, treatment with this flavone (10 μg/kg) decreased plasma LDH 590 
and NO• levels, and also down-regulated iNOS protein and mRNA expressions [101]. 591 
 592 
 More recently, diosmin cardioprotective effects have been shown by Senthamizhselvan et al. 593 
[102], who observed significant decrease of LDH and creatine kinase (CK)-MB activities, along with 594 
increased levels of glutathione and antioxidant enzymes SOD, CAT and GSH-px activities on 595 
Langendorff-I/R rats. Moreover, lipid peroxidation and in vitro O2•- and OH• generation were reversed by 596 
diosmin. 597 
Despite the few studies demonstrating the effects of flavones on the ischemic-associated 598 
oxidative stress, many others have been performed reporting the efficacy of several flavones (including 599 
apigenin, scutellarin, chrysin among others) in the protection of myocardial I/R injuries through 600 
interaction with other signaling pathways such as PI3K/Akt, MAPK and apoptotic cascade pathways, and 601 
NF-kB activation [103-107]. 602 
  603 
 604 
Table 4. Protective effect of flavones on coronary heart diseases.    605 
Compound Model Test conditions Effects Ref 
Apigenin, 
Luteolin 
EA.hy926 
40 µM for 2h 
prior to a 24h 
incubation with 
100 µg/mL 
oxLDL 
↑ Cell viability; ↓ MDA levels; ↑ NO• release; ↓ ICAM-1 [95] 
Diosmin I/R rat 
50 and 100 mg/kg 
for 30 min prior to 
I/R, oral 
administration 
↑ rate pressure product; ↓ LDH release; ↓ CK-MB expression; ↑ 
SOD/CAT/GPx activity; ↑ GSH levels; ↓ TBARS/LOOH levels; ↑ 
mitICDH/mitMDH activity; ↑ mit α-KGDH activity; ↑ mitSDH 
activity; ↑ ATP level; ↓ Bcl-2 downregulation 
[102] 
Luteolin, 
Apigenin 
EA.hy926 
40 µM for 2h 
prior to 24h 
incubation with 
100 µg/mL 
oxLDL 
Inhibited oxLDL-induced cytotoxicity; ↓ ROS generation; ↓ O2˙
- 
generation; ↓ p38MAPK phosphorylation; ↓ NF-kB translocation 
to nucleus; ↓ NF-kB-mediated transcriptional activity; ↓ NF-kB-
mediated gene expression activity of ICAM-1, VCAM-1, E-
selectin, MMP-1/-2/-9 
[96] 
Luteolin 
HUVECS 
6.25, 12.5, 25 µM 
for 12h prior to 
24h with TNF-α 
50 ng/mL 
↓ LDH release; ↑ SOD activity; ↑ GSH activity; ↓ ROS 
generation; ↓ Nox-4 and p22phox mRNA/protein expression, 
caspase-3/-9, ICAM-1, VCAM-1 expression, nuclear p65 levels 
and p65, p38 and ERK1/2 phosphorylation; ↑ Bcl-2 expression 
and IkB-α cytosolic levels 
 
[97] 
Myocardial I/R 
rat 
0.01-10 µg/kg 
prior to ischemia 
0.01-1 µg/kg prior 
to reperfusion, 
jugular vein 
injection 
↓ Ischemia- and reperfusion-induced arrhythmias; ↓ LDH 
expression and NOx release; ↓ myocardial infarct area; ↓ iNOS 
mRNA/protein expression; ↓ MDA levels 
[101] 
I/R rat 
40 µmol/L for 30 
min before I/R, 
Ameliorates I/R-induced impairment of hemodynamic parameters; 
↓ infarct area; ↓ LDH release 
[103] 
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perfusion 
Cardiomyocytes 
in simulated I/R 
2, 4, 8, 16 µmol/L 
↑ shortening amplitude; ↑ Bcl-2 expression; ↓ Bax expression; ↓ 
apoptotic cells; ↑ total Akt, PLB expression levels; ↑ p-Akt/p-
PLB/SERCA2a expression 
Cardiomyocytes 
in simulated I/R 
0.5, 1.5, 2.5, 5.0 
µg/mL 
↓ necrotic cells; ↓ LDH release; ↑ shortening amplitude; ↓ 
apoptotic cells; ↓ caspase-3/Bax expression; ↑ Bcl-2 expression; 
ameliorated cardiac systolic/diastolic function and heart rate 
[106] 
I/R on STZ-
induced 
diabetic rats 
10 µg/kg for 30 
min prior to I/R, 
tail vein injection 
↓ LDH release; ↓ Arrhythmic events; ↓ Infarct area; ↑ 
hemodynamic parameters on left ventricle; ↓ apoptotic cells; ↓ 
caspase-3; ↑ FGRF2, LIF, Bcl-2 expression and Akt and BAD 
phosphorylation; ↓ Bax expressin; ↓ MPO activity; ↓ IL-6/IL-
1α/TNF-α levels 
[104] 
I/R rat model 40 µmol/L 
↓ hemodynamic parameters impairment; ↓ infarct area; LDH 
release; ↓ apoptotic cells 
[107] 
Cardiomyocytes 
in simulated I/R 
2, 4, 8, 16 µmol/L 
↓ necrotic cells; ↓ LDH release; ↑ shortening amplitude; ↑ p-
ERK1/2, Bcl-2, SERCA2a and p-PLB levels; ↓ p-JNK, Bax and p-
PP1 levels 
6-OHFlav – 6-hydroxyflavone; 7-OHFlav – 7-hydroxyflavone; Akt – protein kinase B; Api – apigenin; BAD – Bcl2-associated death promoter; Baic – 606 
baicalein; CAT – catalase; Chr – chrysin; CK-MB – creatine kinase-MB; DS – Diosmin; EA.hy926 – human umbilical vein cell line; ERK1/2 – 607 
extracellular signal-regulated kinase; FGFR2 – fibroblast growth factor receptor 2; Flav – flavone; GPx – glutathione peroxidase; GSH – reduced 608 
glutathione; HUVECS - Human Umbilical Vein Endothelial Cells; I/R – ischemia/reperfusion; ICAM-1 – intracellular adhesion molecule-1; IL-6/-1α – 609 
interleukin-6/-1α; JNK – c-Jun N-terminal kinase; LDH – lactacte dehydrogenase; LIF – leukemia inhibitory factor; LOOH – peroxide; Lut – luteolin; 610 
MAPK – mitogen-activated protein kinase; MDA – malondialdehyde; mitICDG – mitochondrial isocitrate dehydrogenase; mitMDH – mitochondrial 611 
malate dehydrogenase; mitSDH – mitochondrial succinate dehydrogenase; mitαKGDH – mitochondrial α-ketoglutarate dehydrogenase; MMP-1/-2/-9 – 612 
matrix metalloproteinase-1/-2/-9; MPO – myeloperoxidase; NF-kb – nuclear factor-kappa B; Nox4 – NADPH oxidase-4: oxLDL – oxidized low 613 
density lipoprotein; P22phox - human neutrophil cytochrome b light chain, NAD(P)H oxidase essential component 614 
 615 
4. CONCLUSION 616 
Flavones are phenyl substituted chromones characterized by the presence of a double bond 617 
between 2 and 3 position in the heterocyclic C-ring and the lacking of oxygenation at the 3-position of the 618 
same ring. These compounds have been the focus of attention of much research, due to their potential 619 
health benefits. Particular emphasis has been given to their antioxidant capacities, which can occur 620 
through direct and/ or indirect ways. 621 
Chronic and acute neurological insults, diabetes and atherosclerosis are pathological disorders 622 
closely associated with oxidative stress. Indeed, promising results regarding to the protective effects of 623 
some flavones have been demonstrated in in vitro and in vivo models of such diseases. However, further 624 
research needs to be done in order to better comprehend the mechanisms underlying these protective 625 
effects. Still, the introduction of flavonoids and/or flavones rich foods in our diet, can be the first step to 626 
prevent of the development oxidative stress diseases. 627 
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